Institutional shares held 69.4 Million
220K calls
310K puts
Total value of holdings $1.56B
$4.94M calls
$6.97M puts
Market Cap $1.05B
46,772,400 Shares Out.
Institutional ownership 148.36%
# of Institutions 189


Latest Institutional Activity in CLDX

Top Purchases

Q2 2025
Sovran Advisors, LLC Shares Held: 39.5K ($887K)
Q2 2025
Mirador Capital Partners LP Shares Held: 159K ($3.56M)
Q2 2025
Versant Capital Management, Inc Shares Held: 214 ($4.81K)
Q1 2025
Wellington Management Group LLP Shares Held: 8.35M ($188M)
Q1 2025
Commodore Capital LP Shares Held: 3.2M ($71.9M)

Top Sells

Q2 2025
Parallel Advisors, LLC Shares Held: 74 ($1.66K)
Q1 2025
Jefferies Financial Group Inc. Shares Held: 55K ($1.24M)
Q1 2025
Woodline Partners LP Shares Held: 1.19M ($26.7M)
Q1 2025
Goldman Sachs Group Inc Shares Held: 696K ($15.6M)
Q1 2025
Morgan Stanley Shares Held: 903K ($20.3M)

About CLDX

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-0159, a Phase I monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity; CDX-1140, a human agonist monoclonal antibody targeted to CD40, a key activator of immune response, which is found on dendritic cells, macrophages, and B cells, as well as is expressed on various cancer cells; and CDX-527, a bispecific antibody, which uses the company's proprietary active anti-PD-L1 and CD27 human antibodies to couple CD27 costimulation with blockade of the PD-L1/PD-1 pathway to help prime and activate anti-tumor T cell responses through CD27 costimulation. The company has research collaboration and license agreements with University of Southampton to develop human antibodies towards CD27; Amgen Inc. with exclusive rights to CDX-301 and CD40 ligand; and Yale University. Celldex Therapeutics, Inc. was incorporated in 1983 and is headquartered in Hampton, New Jersey.


Insider Transactions at CLDX

Insider Transaction List

View all
Date Insider Transaction Ownership Type Shares Traded Value / Price
View All Transactions

Last 12 Months Summary

Buy / Acquisition
11.5K Shares
From 1 Insiders
Open market or private purchase 11.5K shares
Sell / Disposition
10.5K Shares
From 1 Insiders
Bona fide gift 10.5K shares

Track Institutional and Insider Activities on CLDX

Follow Celldex Therapeutics, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells CLDX shares.

Notify only if

Insider Trading

Get notified when an Celldex Therapeutics, Inc. insider buys or sells CLDX shares.

Notify only if

News

Receive news related to Celldex Therapeutics, Inc.

Track Activities on CLDX